<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="625">
  <stage>Registered</stage>
  <submitdate>2/08/2005</submitdate>
  <approvaldate>2/08/2005</approvaldate>
  <nctid>NCT00126360</nctid>
  <trial_identification>
    <studytitle>STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing Pilot)</studytitle>
    <scientifictitle>Pilot for a Randomised Comparison of Anastrozole Commenced Before and Continued During Adjuvant Radiotherapy for Breast Cancer Versus Anastrozole and Subsequent Ant-Oestrogen Therapy Delayed Until After Radiotherapy</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>STARS-Pilot (05/55 Graham)</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Breast Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Timing of Anastrozole in respect to radiotherapy

Treatment: drugs: Timing of Anastrozole in respect to radiotherapy


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Local failure within irradiation volume</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Early quality of life</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Lung fibrosis</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Also demonstration of recruitment capacity at lead trial centres</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Age 18 or more years. No upper limit.

          -  Post total mastectomy or lumpectomy. All planned surgery complete.

          -  Margins clear (no tumour contacting the inked margin)

          -  Tumour oestrogen or progesterone receptor positive

          -  Planned dose to irradiated volumes at least the biological equivalent of 45 Gy in 25
             fractions or more.

          -  ECOG 0-2

          -  Patients post menopausal using same criteria as ATAC study.

          -  Written informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Previous radiotherapy to the area to be treated.

          -  Previous invasive malignancy within 5 years of current breast cancer diagnosis with
             the exception of cervix in-situ or skin cancer other than melanoma.

          -  Patients with clinical evidence of metastatic disease.

          -  Previous hormonal breast therapy.

          -  Ongoing hormone replacement therapy.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD</recruitmentstate>
    <hospital>Liverpool Hospital - Sydney</hospital>
    <hospital>St George Hospital - Sydney</hospital>
    <hospital>Campbelltown Hospital - Sydney</hospital>
    <hospital>Princess Alexandra Hospital - Brisbane</hospital>
    <postcode>2170 - Sydney</postcode>
    <postcode>2217 - Sydney</postcode>
    <postcode>2560 - Sydney</postcode>
    <postcode>4102 - Brisbane</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>St George Hospital, Australia</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>AstraZeneca</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a randomized study comparing the use of Anastrozole before and continuing during
      radiotherapy for breast cancer compared to the use of anastrozole after irradiation.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00126360</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Ass. Prof. Peter H Graham, MBBS FRANZCR</name>
      <address>Cancer Care Centre, St George Hospital, Sydney</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Ass. Prof. Peter H Graham, MBBS FRANZCR</name>
      <address />
      <phone>+61 293503934</phone>
      <fax />
      <email>GrahamP@sesahs.nsw.gov.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>